Biomarker Finder
Biomarker Finder: blood biomarkers for your CNS trial
Answer three questions to get a suggested starting panel of blood biomarkers for your neurodegenerative disease trial. Our scientists then confirm it against your samples in a free sample-feasibility review.
Suggested starting panel
Parkinson’s / Lewy body · Phase 2 · target engagement
- 1Drug-pathway markers in brain-derived EVsShow the drug engaged its target in the brain.
SamplingBaseline plus 2–3 on-treatment draws
Sample per timepoint500 µL EDTA plasma or serum
TurnaroundTypically 2–3 weeks from sample receipt
How to use the suggestion
Plasma or brain-derived EVs?Plasma works for markers made mostly in the brain, like NfL and p-Tau217. Proteins also made elsewhere, like α-synuclein and TDP-43, are measured in brain-derived EVs. Compare the approaches
Validated analytesSee which markers are clinical LDT, qualified, published or available as ready-to-use panels. View the analyte list
Clinical-trial supportFrom study design to sample logistics and data delivery. Clinical trial services
Frequently asked questions
How does the Biomarker Finder choose markers?
It starts from the blood biomarkers with the strongest published evidence for the chosen indication, then reorders them for your trial goal. It is a starting point; our scientists confirm the final panel in a sample-feasibility review.
Can I combine plasma and brain-derived EV biomarkers in one study?
Yes. Many programs pair plasma markers of injury or pathology, such as NfL or p-Tau217, with brain-derived EV markers of mechanism, from the same blood draw.
How much sample is needed?
A minimum of 500 µL of EDTA plasma or serum per timepoint, shipped frozen on dry ice.

